New York, United States, July 15th, 2026, FinanceWireAtlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have defined its track record since launch — none more striking than its position in Eli Lilly and Company, entered at approxim…
Cathie Wood's ARK Invest increased positions in several technology, healthcare and digital asset companies during the week ended July 10, while reducing holdings in select semiconductor and genomics names.Space Exploration Technologies NASDAQ:SPCX represented the firm's largest purchase by value, w…
Eli Lilly (LLY, Financials), the pharmaceutical company known for diabetes, obesity, oncology and immunology treatments, got a lift after Canada's Drug Agency issued a positive recommendation for Ebglyss.Ebglyss is used to treat patients with moderate-to-severe eczema, a chronic skin condition that…
What Happened? Shares of global pharmaceutical company Eli Lilly NYSE:LLYjumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.Schott's $1,400 target sits above the roughly $1,243 Street average and signals…
Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the P.R.O.O.F phase of its CXU preclinical program, the evidence base behind a focused first move into a roughly $11 billion medical aesthetics injectable market, an opening the company argues today's tools were…
(12:37 GMT) Eli Lilly Price Target Raised to $1400.00/Share From $1300.00 by JP Morgan
By Paul R. La MonicaNervous about all the volatility in semiconductor stocks and the broader tech sector? Healthcare stocks might offer some safety.The sector boasts steady dividends, solid fundamentals, and the potential for a boost from more merger activity, especially among smaller biotechs. And…
(13:00 GMT) Eli Lilly Price Target Raised to $1350.00/Share From $1230.00 by Cantor Fitzgerald
Scribe Therapeutics Stockholders Include Eli Lilly
Eli Lilly and Company’s LLY stock has risen around 6.7% in a week, backed by strong company-specific news and the overall recent rally in the U.S. drug and biotech sector. Eli Lilly stock hit a new 52-week high on June 26. Last week, the European Medicines Agency's Committee for Medicinal Products…
By Sai Ishwarbharath B and Rishika SadamMedical device maker Zimmer Biomet NYSE:ZBH plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expands its presence in India.The hires will span softwa…
By David WainerMedicare began covering weight-loss drugs for seniors this week. For patients long shut out from the GLP-1 boom, the opening is a real milestone. For Wall Street, it isn't the immediate windfall the headlines suggest.Drugs such as Wegovy and Zepbound have rocketed into the national s…
Cathie Wood's ARK Invest increased its exposure to artificial intelligence, digital assets and next-generation healthcare during the week of June 22 to 26, while reducing positions in streaming and Chinese technology companies.ARK Invest added to several AI-related holdings, including Cerebras Syst…
Cathie Wood's ARK Invest increased its exposure to artificial intelligence, digital assets and next-generation healthcare during the week of June 22 to 26, while reducing positions in streaming and Chinese technology companies.ARK Invest added to several AI-related holdings, including Cerebras Syst…
By Chris Prentice and Amina NiasseMillions more Americans will qualify for obesity medications at just $50 a month under a new Medicare program starting on Wednesday, bringing the highly effective drugs to people aged 65 and older at an affordable price.The U.S. Centers for Medicare & Medicaid Serv…
By Mariam Sunny and Sneha S KMillions of Americans are expected to gain coverage for GLP-1 drugs for weight loss under a new U.S. pilot launching on Wednesday in its Medicare program for people aged 65 and older or with disabilities that will offer the medications for a monthly co-pay of $50.Eligib…
By Peter LoftusMillions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.Medicare will pilot a program, dubbed Bridge, to offer three weight-loss drugs for eligible members, who would pay $50 monthly c…
By Catherine DunnThe federal Medicare agency is expanding access to weight loss drugs under a new temporary program starting Wednesday. Millions of people may be eligible for medication, but it may not lead to an immediate boon for Novo Nordisk and Eli Lilly.Analysts are watching patient uptake for…
Eli Lilly (LLY, Financials) is turning to Innovent Biologics to handle sales of Verzenio in mainland China. The breast cancer drug has been available there since 2021. Last year, it generated about 1.5 billion yuan, or $221 million, in China sales, according to Jefferies data cited by Reuters.Innov…
Some weeks are about a single headline. This one is about a convergence.As the second half of 2026 gets underway, investors are digesting a Federal Reserve that just reset its tone under new leadership, an interest-rate outlook that has quietly flipped on its head, a jobs report that could decide w…
